Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations

    January 2024 in “ Curēus ”
    Philip A Holubeck, Andrew C Eksi, K Gillett, James O’Hara, Daniel J McGoldrick, D. Clayton Brown, Alec McCarthy
    Image
    Studysummary This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly. Our plain-language summary of this paper — not a Tressless recommendation.
    This study investigates the trends in interest for performance-enhancing drugs (PEDs) and related ancillary compounds, highlighting a significant rise in interest for selective androgen receptor modulators (SARMs) like RAD-140, while interest in anabolic steroids and post-cycle therapies remains stagnant or decreases. The authors suggest using social and prescription data as proxies to help clinicians better understand and adapt to these trends, given the lack of clinically relevant data and evidence-based approaches for monitoring PED use and its adverse effects.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results